IA
VERV

IFP Advisors’s Verve Therapeutics VERV Stock Holding History

IFP Advisors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,026
Closed -$112K – 5047
2025
Q3 		$112K Buy
10,026
+387
+4% +$4.29K ﹤0.01% 1616
2025
Q2 		$117K Buy
9,639
+1,401
+17% +$7.99K ﹤0.01% 1545
2025
Q1 		$37.8K Hold
8,238
– – ﹤0.01% 2021
2024
Q4 		$46.6K Buy
8,238
+8,237
+823,700% +$46.5K ﹤0.01% 1865
2024
Q3 		$5 Hold
1
– – ﹤0.01% 3291
2024
Q2 		$5 Hold
1
– – ﹤0.01% 3219
2024
Q1 		$13 Hold
1
– – ﹤0.01% 3098
2023
Q4 		$14 Hold
1
– – ﹤0.01% 3018
2023
Q3 		$13 Sell
1
-5
-83% -$81 ﹤0.01% 3270
2023
Q2 		$112 Buy
+6
New +$100 ﹤0.01% 3348
2023
Q1 		– Sell
-100
Closed -$3K – 4405
2022
Q4 		$3K Buy
+100
New +$2.65K ﹤0.01% 4070

Other funds holding VERV

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors's VERV Position: Q4 2025 in Review

IFP Advisors sold out of Verve Therapeutics (VERV) in Q4 2025, closing a stake of 10,026 shares — an estimated $112K sold.

IFP Advisors first reported a position in VERV in Q4 2022 and held it in 11 quarters. The position peaked at $117K in Q2 2025. 1 fund tracked by Wall St. Rank holds VERV as of Q4 2025.

  • IFP Advisors reported no remaining Verve Therapeutics position as of Q4 2025 after selling out during the quarter.
  • IFP Advisors sold 10,026 Verve Therapeutics shares in Q4 2025, an estimated $112K.
  • IFP Advisors first reported a position in Verve Therapeutics in Q4 2022 and held it in 11 quarters.
  • IFP Advisors's Verve Therapeutics position peaked at $117K in Q2 2025.
  • 1 fund tracked by Wall St. Rank held Verve Therapeutics as of Q4 2025.

Based on IFP Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.